Dr. Haidry is a Consultant Gastroenterologist and interventional endoscopist at University College Hospital, London. He trained at St Mary’s Hospital in London and completed his Specialist Gastroenterology training in North East London. He was then appointed to a two-year academic fellowship at UCLwhere he examined state of the art and innovative diagnostic and therapeutic endoscopic techniques for the diagnosis and treatment of early cancers arising in thegastrointestinal tract.
He was appointed as a consultant in 2011. He is the director of endoscopy for the division of gastroenterology at University College Hospital and leads the upper GI interventional endoscopic unit. His main interests are pre-malignant and malignant disorders of the upper gastrointestinal tract, with a particular interest in Barrett’s neoplasia, oesophageal cancer and advanced interventional endoscopy.He also hosts several live endoscopy workshops each year at UCH focusing on novel and innovative endoscopic imaging techniques and therapeutic endoscopic courses focusing on endoscopic resection, radiofrequency ablation, endoscopic ultrasound and complex stricture management.
He has an academic position at UCL exploring existing and novel endoscopic imaging technologies for detecting early cancers. His other main research focus is minimally invasive techniques for treating cancers of the upper gastrointestinal tract and continues tolead and be involved actively on several national and international clinical trials in these fields.
He is enthusiastic about embracing new and innovative endoscopic technologies and has within the past few years
Dr. Haidry and his team performing an endoscopy procedure at the highly acclaimed unit at University College Hospital
Dr. Haidry seeing a patient in his rooms at the London Gastroenterology Centre. He often uses multimedia formats to help explain conditions and tests to his patients Patient Centred ApproachResearchTraining ExcellenceProfessional MembershipsPublicationsPatient ReviewsWhat's New
Dr. Haidry has an individualized and tailored approach for each patient he manages. He states,“No two patient’s are the same. It is possible to narrow down the cause of a very vague symptom such as abdominal pain, bloating or unexplained reflux by taking a precise medical history, performing a thorough clinical examination and then carefully choosing the appropriate tests to make an accurate diagnosis”
Dr. Haidry goes on to state,“Armed with the correct diagnosis, I then engage all my patients to explain the options available. I like to work with each patient to set up an individual treatment plan with realistic time lines and achievable outcomes”.
Dr. Haidry also appreciates that the signs and symptoms for the various problems that patients present to him can be long standing and affect people’s quality of life on a daily basis. He explains,“several of the symptoms and conditions that patients come to see me with are often embarrassing to talk about and patients feel they are unique. By reassuring them that actually there are many other patients with similar problems, and that help is available, one can start to improve their outlook on their symptoms”
Dr. Haidry aspires to clinical excellence. “I feel it is very important to deliver the highest quality of care to all my patients. This is the case whether they come to see me in my busy NHS practice at University College London Hospital or for a private consultation at the London gastroenterology centre”.
Dr. Haidry has a very balanced approach to his work and personal life. He says “I am dedicated to my patients and passionate about the work I do in my NHS practice, all my research projects and private practice. However I ensure that I have a very balanced approach to life and my time with my family and children is very precious and special to me”.
Dr. Haidry has is actively involved in several research projects at world leading University College Londonand continues to bepublished in several leading journals in his field. He says,“I am fully committed to high quality clinical research to provide innovative and state of the art care to our patients. This is why I am involved in several important clinical trials and why I continue to push the boundaries of research excellence through my role as Honorary Senior Research Associate at University of London”.
Dr. Haidry regularly speaks conferences, seen here lecturing at the national British Society of Gastroenterology meeting
Dr. Haidry seen here giving a lecture at one of the several courses he runs on new endoscopic procedures and techniques
Dr. Haidry performing live endoscopy demonstrations at the BSG meeting in Liverpool on June 2016
His research interests are focused on developing new methods for detecting and treating dysplasia (early cancer) in Barrett’s Oesophagus and other pathologies of the gastrointestinal tract. He coordinates and runs one of Europe’s largest endoscopy registries, the UK Radiofrequency ablation registry,which collects nationwide outcomes of this exciting new intervention in patients with early cancer of the oesophagus. He explains “The outlook for patients with oesophageal cancer is poor in our country due to the fact that we often diagnose them late. By diagnosing patients with reflux and Barrett’s Oesophagus early we are now successfully treating many patients with early oesophageal cancer and really making a difference.”
He is currently looking at new procedures such as cryoablation for freezing away early cancers of the oeosphagus – this appears to be an exciting technology for the future. He was the first to perform cryo-ablation for patients with Barrett’s oeosphagus and early squamous cancer in the UK.
He is also exploring endoscopic approaches to treat patients with Type 2 Diabetes Mellitus which affect over 3 million people in the United Kingdom.Duodenal mucosal resurfacing (DMR) is an innovative and novel endoscopic intervention for the treatment of patients with poorly controlled Type 2 DM. The first ever cases in the UK have been carried out by Dr. Rehan Haidry at UCLH in the 2015. Carefully selected patients with Type 2 DM have undergone successful treatment as part of a multi-center study (Amsterdam, Brussels, Rome) with 3 month follow up showing improvements in glycemic control in all patients treated to date. Further recruitment is in place for the next series of cases in 2016. This intervention shows early promise to provide a new treatment paradigm for patients with diabetes. (www.revitatrial.co.uk)
This new technique was recently reviewed in the Wall street Journal and Daily mail– click on the link to learn more and see video interview with Dr Haidry.
In 2016 Dr Haidry will be initiating a state of the art trial looking at a new interventioncalledcryoablation for the treatment of patients with earlyoesophageal cancer. The procedure was pioneered in the USA and has been used in over 100 patients in Johns Hopkins Hospital. The technique uses the concept the freezing the abnormal cells in the superficial layers of the oeosophagus to destroy them and has shown some very promising results in the early studies.
Dr. Haidryis regularly invited to attend and present at both local and international conferences, using these as a forum to share his research findings but also learn from what others are doing in the field of diagnosis and treatment of gastrointestinal cancers. He is actively involved in teaching and coordinates several state of the art endoscopy training courses at UCLH.
Dr Haidry is the lead for the Pentax Training Centre of excellence program, and the endoscopy unit at UCLH is the only UK center involved in this prestigious European initiative. More details are available on www.training-for-excellence.eu. He has also the clinical lead at ULCH for BEST academia which is a European RFA training program. This is designed to train clinicians involved in the diagnosis and treatment of early Barrett’s cancer with RFA. The inaugural start of the art course was run in March 2014, with the next one open to registration in November 2014. See more details at best-academia.eu.
For all appointments and enquiries, please callDr.Haidry’s secretary on 020 7183 7965 or Mobile: 07960 389738 or E-mail: email@example.com
Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer. Di Caro S, Cheung WH, Fini L, Keane MG, Theis B, Haidry R et al. Eur J GastroenterolHepatol. 2015 Dec 14.
Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett’s associated neoplasia.Kohoutova D, Haidry R, Banks M, Bown S, Sehgal V, Butt MA, Graham D, Thorpe S, Novelli M, Rodriguez-Justo M, Lovat L. Scand J Gastroenterol. 2015 Nov;50(11):1315-21. doi: 10.3109/00365521.2015.1043578. Epub 2015 May 8.
Long-term durability of radiofrequency ablation for Barrett’s-related neoplasia.Kohoutova D, Haidry R, Lovat L. CurrOpinGastroenterol. 2015 Jul;31(4):316-20.
Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry.Haidry Ret al.Endoscopy. 2015 Jun 30. [Epub ahead of print].
Radiofrequency Ablation for Barrett’s Dysplasia: Past, Present and the Future?. Haidry R, Lovat L, Sharma P. CurrGastroenterol Rep. 2015 Mar;17(3):433. doi: 10.1007/s11894-015-0433-5.
Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett’s oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry Haidry Ret al. Gut doi:10.1136/gutjnl-2014-308501
Primary malignant melanoma of the esophagus. Wallis G, Sehgal V, Haider A, Bridgewater J, Novelli M, Dawas K, Haidry R. Endoscopy. 2015;47Suppl 1 UCTN:E81-2. doi: 10.1055/s-0034-1391126. Epub 2015 Feb 17
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC; BEST2 Study Group.PLoS Med. 2015 Jan 29;12(1):e1001780. doi: 10.1371/journal.pmed.1001780.2015 Jan.
Clonal Selection and Persistence in Dysplastic Barrett’s Esophagus and Intramucosal Cancers After Failed Radiofrequency Ablation. Zeki SS, Haidry R, Graham TA, Rodriguez-Justo M, Novelli M, Hoare J, Dunn J, Wright NA, Lovat LB, McDonald SA. Am J Gastroenterol.2013 Aug 13.doi: 10.1038/ajg.2013.238
Radiofrequency Ablation For Esophageal Squamous High Grade Dysplasia And Early Squamous Cell Carcinoma: Outcomes From The United Kingdom Halo Radiofrequency Ablation National Registry. Haidry Rehan et al. World Journal of gastroenterology, World J Gastroenterol2013, 19 volume 36 issue
Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett’s Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry. Rehan J. Haidry, Jason M. Dunn, Mohammed A. Butt, Matthew G. Burnell, et al. Gastroenterology 2013;145:87–95
Squamous cell cancer after radiofrequency ablation for Barrett’s dysplasia. Sebastian S. Zeki, Rehan Haidry et al,World Journal of Gastroenterology ESPS Manuscript No: 4597
A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett’s oesophagus. Dunn JM, Mackenzie GD, Banks MR, Mosse CA, Haidry R, Green S, Thorpe S, Rodriguez-Justo M, Winstanley A, Novelli MR, Bown SG, Lovat LB. Lasers Med Sci. 2012 Jun 15.
Polyp detection is improved by megapixel white light high resolution Colonoscopy in the UK National Bowel cancer screening program. Matthew R Banks, Rehan J Haidry et al. World Journal Gastroenterology: Ms No: wjg/2011/02873
More than 90% of patients who took our survey were ‘very’ or ‘extremely’ satisfied with Dr Haidry
More than 90% of patients who took our survey felt that Dr Haidry listened very or extremely well to them